Efficacy and Safety of the Modified EPOCH Regimen (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Adult T-cell Leukemia/Lymphoma: A Multicenter Retrospective Study.

[1]  Joel P Frank,et al.  Making moves: Transitioning R-EPOCH to the ambulatory setting , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[2]  H. Abel,et al.  Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma , 2016, Blood Cancer Journal.

[3]  S. Yamasaki,et al.  Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma , 2016, Bone Marrow Transplantation.

[4]  M. Seto,et al.  Recent advances in the treatment of adult T-cell leukemia-lymphomas , 2015, Cancer science.

[5]  R. Ueda,et al.  Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study , 2015, British journal of haematology.

[6]  R. Fisher,et al.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma , 2013, Cancer.

[7]  T. Yamanaka,et al.  Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Yamanaka,et al.  Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials , 2011, Bone Marrow Transplantation.

[9]  A. Bazarbachi,et al.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Matsuo,et al.  Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. , 2010, Blood.

[11]  J. Rossi,et al.  Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95 , 2010, British journal of haematology.

[12]  A. Utsunomiya,et al.  THP‐COP regimen for the treatment of peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma: a multicenter phase II study , 2010, European journal of haematology.

[13]  J. Sparano,et al.  Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma , 2009, PloS one.

[14]  K. Yamaguchi,et al.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Ueda,et al.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Niitsu,et al.  Salvage chemotherapy for relapsed or refractory non‐Hodgkin's lymphoma with a combination of ACES (high‐dose Ara C, carboplatin, etoposide and steroids) therapy , 1996, European journal of haematology.

[17]  S. Johnson,et al.  Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule—epic , 1994, Hematological oncology.

[18]  W. Wilson,et al.  EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[20]  K. Uozumi,et al.  Expression of P-glycoprotein in adult T-cell leukemia cells. , 1990, Blood.

[21]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .